Auron and Elucidata Launch AI Driven Collaboration to Identify Targets for Differentiation-Based Oncology Therapies

Auron Therapeutics and Elucidata Corporation on 12/19/18 announced a scientific collaboration using Elucidata’s AI-based target discovery platform to identify and validate targets for differentiation9-based therapy for Acute Myeloid Leukemia (AML) and eight other oncology indications.